Table 1:

Significant vimentin immunoreactivity patterns.

Vimentin immunoreactive carcinomas Renal cell carcinoma (except the chromophobe variant) Adrenal cortical carcinoma Endometrial adenocarcinoma (Endometrial endometrioid carcinomas immunostain strongly for vimentin, but endocervical carcinomas rarely stain (weak focal staining in up to 13% of endocervical carcinomas). Malignant mixed Müllerian tumors, serous ovarian carcinomas Large cell carcinoma of lung Metaplastic carcinoma of breast Poorly differentiated adenocarcinoma of stomach (6%) Sarcomatoid carcinomas (spindle cell carcinomas) Pleomorphic salivary gland tumors “Basal-like” breast carcinomas Follicular and anaplastic thyroid carcinomas Epithelial and sarcomatoid mesotheliomas Solid pseudopapillary neoplasm of the pancreas Vimentin expressing tumor epithelial cells in surgically resected carcinomas including pancreatic adenocarcinomas and hepatocellular carcinoma independently predicted a shorter post-surgical survival Vimentin non-immunoreactive sarcoma Alveolar soft part sarcoma